Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin

Background & Aims: Recently, we reported that liver Label Retaining Cancer Cells (LRCC) can initiate tumors with only 10 cells and are relatively resistant to the targeted drug Sorafenib, a standard of practice in advanced hepatocellular carcinoma (HCC). LRCC are the only cancer stem cells (CSC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Hong-Wu, Ambe, Chenwi M., Miller, Tyler C., Chen, Jin-Qiu, Wiegand, Gordon W., Anderson, Andrew J., Ray, Satyajit, Mullinax, John E., Hari, Danielle M., Koizumi, Tomotake, Godbout, Jessica D., Goldsmith, Paul K., Stojadinovic, Alexander, Rudloff, Udo, Thorgeirsson, Snorri S., Avital, Itzhak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911882/
https://www.ncbi.nlm.nih.gov/pubmed/27326258
http://dx.doi.org/10.7150/jca.10047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911882/
https://www.ncbi.nlm.nih.gov/pubmed/27326258
http://dx.doi.org/10.7150/jca.10047

Ejemplares similares